Heather E. Whitson, Nicole R. Fowler, Michelle M. Mielke
This Viewpoint discusses areas of potential harm and actions needed to mitigate risk so that the use of blood-based biomarkers for Alzheimer disease can achieve the intended goal of improving care for all.